Canada Markets closed
  • S&P/TSX

    20,491.01
    +284.60 (+1.41%)
     
  • S&P 500

    4,088.85
    +80.84 (+2.02%)
     
  • DOW

    32,654.59
    +431.17 (+1.34%)
     
  • CAD/USD

    0.7804
    -0.0004 (-0.0515%)
     
  • CRUDE OIL

    114.09
    +1.69 (+1.50%)
     
  • BTC-CAD

    38,969.41
    +305.85 (+0.79%)
     
  • CMC Crypto 200

    684.04
    +441.36 (+181.87%)
     
  • GOLD FUTURES

    1,814.70
    -4.20 (-0.23%)
     
  • RUSSELL 2000

    1,840.30
    +56.87 (+3.19%)
     
  • 10-Yr Bond

    2.9680
    +0.0910 (+3.16%)
     
  • NASDAQ futures

    12,544.00
    -16.25 (-0.13%)
     
  • VOLATILITY

    26.10
    -1.37 (-4.99%)
     
  • FTSE

    7,518.35
    +53.55 (+0.72%)
     
  • NIKKEI 225

    26,977.32
    +317.57 (+1.19%)
     
  • CAD/EUR

    0.7393
    -0.0004 (-0.05%)
     

Syros to Participate in Upcoming Investor Conferences

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

CAMBRIDGE, Mass., November 16, 2021--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in fireside chats at two upcoming virtual investor conferences. Management will also be available for one-on-one meetings.

Piper Sandler 33rd Annual Healthcare Conference
Date: Tuesday, November 23, 2021
Presentation Time: A pre-recorded fireside chat will be made available on-demand beginning at 10:00 a.m. ET

JMP Securities Hematology and Oncology Summit
Date: Monday, December 6, 2021
Presentation Time: 10:40 a.m. ET

To access the webcasts and subsequent archived recording of each fireside chat, please visit the Investors & Media section of the Syros website at www.syros.com. An archived replay of each webcast will be available for approximately 30 days following each presentation.

About Syros Pharmaceuticals
Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust clinical-stage pipeline, including: tamibarotene, a first-in-class oral selective RARα agonist in RARA-positive patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia; and SY-5609, a highly selective and potent oral CDK7 inhibitor in patients with select solid tumors and blood cancers. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211116005077/en/

Contacts

Media Contact:
Courtney Solberg
Syros Pharmaceuticals
917-698-9253
csolberg@syros.com

Investor Contact:
Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
hannah.deresiewicz@sternir.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting